| Edurant (rilpivirine) / J&J |
2012-002663-10: Darunavir/ritonavir and rilpivirine in therapy-naïve patients. |
|
|
| Completed | 4 | 40 | Europe | Edurant (rilpivirine), Prezista (darunavir), Norvir (ritonavir), Film-coated tablet, Edurant, Prezista, Norvir | St Stephen's AIDS Trust, Janssen-Cilag Ltd | HIV-1, HIV, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR-TRC-14004908: Rilpivirine Versus Efavirenz with Tenofovir and lamivudine's use in treatment-naive adults with HIV-1 infection and injection drug use on Methadone maintenance treatment |
|
|
| Recruiting | 4 | 60 | | taking Rilpivirine RPV+TDF+3TC and methadone ;taking Rilpivirine RPV+TDF+3TC and methadone | Yunnan Provincial Infectious Disease Hospital; Yunnan Provincial Infectious Disease Hospital, Funded by Xian Janssen Pharmaceutical Ltd. | AIDS | | | | |
2014-002284-15: A study to assess changes in Central Nervous System (CNS) function where no obvious symptoms exist, when switching from Atripla to Eviplera switch in HIV infected patients |
|
|
| Completed | 4 | 40 | Europe | Eviplera, Film-coated tablet, Eviplera | St Stephen's AIDS Trust, Gilead Sciences Ltd | HIV, HIV, Diseases [C] - Immune System Diseases [C20] | | | | |
2017-004750-42: EFFICACY AND SAFETY OF A SIMPLIFICATION TREATMENT BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS USUAL TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS WITH MULTIDRUG RESISTANCE. Eficacia y seguridad de Dolutegravir más Darunavir/cobicistat como tratamiento de simplificación frente al tratamiento habitual en pacientes infectados por el VIH-1 virológicamente suprimidos y con resistencia a múltiples fármacos. |
|
|
| Ongoing | 4 | 100 | Europe | lamivudine, Efavirenz, Nevirapine, Film-coated tablet, Coated tablet, Capsule, hard, Tablet, Rezolsta, Tivicay, Ziagen, EMTRIVA, VIREAD, kivexa, Truvada, Intelence, Edurant, Atripla, Eviplera, Reyataz, Prezista, Kaletra, Norvir, Evotaz, Isentress, Stribild, Triumeq, Genvoya, Celsentri, Descovy | FUNDACIÓ LLUITA CONTRA LA SIDA, ViiV Healthcare | HIV-1 VIH-1, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2015-000274-35: clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression. ENSAYO CLÍNICO PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD Y EFICACIA DE DOS ESTRATEGIAS DE SIMPLIFICACIÓN BASADAS EN DOLUTEGRAVIR EN PACIENTES INFECTADOS POR VIH CON SUPRESIÓN VIROLÓGICA SOSTENIDA. |
|
|
| Completed | 4 | 291 | Europe | Lamivudine, Efavirenz, nevirapine, J05AX12, Coated tablet, Capsule, hard, Tablet, Prolonged-release tablet, Film-coated tablet, Tivicay, Stribild, TRUVADA, KIVEXA, ZIAGEN, VIREAD, EMTRIVA, ATRIPLA, EVIPLERA, ISENTRESS, RAYATAZ, PREZISTA, KALETRA, NORVIR, INTELENCE, EDURANT, TRIUMEQ, REZOLSTA, EVOTAZ, GENVOYA | FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA, UNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA, ViiVHealthcare | Infection with human immunodeficiency virus (HIV). Infección por el virus de la inmunodeficiencia humana (VIH)., HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2015-005297-37: Bone Evaluation in women over 40 who Switch from Truvada/NNRTI to Triumeq |
|
|
| Completed | 4 | 90 | Europe | Tenofovir, Lamivudine, Efavirenz, Nevirapine, Etravirine, Rilpivirine, Film-coated tablet, Tablet, Triumeq, Truvada, Atripla, Eviplera | King's College Hospital NHS Foundation Trust, ViiV Healthcare Ltd | Human Immunodeficiency Virus, People infected with Human Immunodeficiency Virus (HIV), Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04340388: Contribution of Dolutegravir to Obesity and Cardiovascular Disease |
|
|
| Completed | 4 | 10 | US | Dolutegravir 50 MG, Tenofovir alafenamide, Tenofovir disoproxil fumarate, Abacavir, Lamivudine, Darunavir, Cobicistat, Rilpivirine, Combivir, Zidovudine, Antiretroviral/Anti HIV, Antiretroviral Combinations | Augusta University | HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome | 06/22 | 02/23 | | |
MAFALDA-R, NCT05898841: Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load |
|
|
| Completed | 4 | 63 | Europe | Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine. | Fundacion SEIMC-GESIDA | HIV Infections, Fatty Liver Disease | 07/25 | 07/25 | | |
GESIDA 12422, 2022-503110-23-00: Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment regimen in HIV-infected patients with metabolic liver disease who maintain undetectable HIV viral load |
|
|
| Completed | 4 | 75 | Europe | Juluca 50 mg/25 mg film-coated tablets, Emtricitabine/Tenofovir disoproxil Tillomed 200 mg/245 mg filmdragerade tabletter, Truvada 200 mg/245 mg film-coated tablets, Descovy 200 mg/25 mg film-coated tablets, Eviplera 200 mg/25 mg/245 mg film-coated tablets, Tivicay 50 mg film-coated tablets, Emtricitabina/Tenofovir disoproxilo Aurovitas 200 mg/245 mg comprimidos recubiertos con pel?cula EFG, Odefsey 200 mg/25 mg/25 mg film-coated tablets, EDURANT 25 mg film-coated tablets | Fundacion Seimc Gesida | Metabolic liver disease in HIV-infected people | | | | |
103900, 2024-515487-31-00: Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) |
|
|
| Completed | 4 | 163 | Europe | Ziagen 300 mg film-coated tablets, INTELENCE 200 mg tablets, Eviplera 200 mg/25 mg/245 mg film-coated tablets, EDURANT 25 mg film-coated tablets, Telzir 700 mg film-coated tablets, TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets, Delstrigo 100 mg/300 mg/245 mg film-coated tablets, Norvir 100 mg film-coated tablets, Ritonavir Accord 100 mg filmomhulde tabletten, Descovy 200 mg/10 mg film-coated tablets, REYATAZ?300?mg hard capsules, REKAMBYS 600 mg prolonged-release suspension for injection, Tivicay 50 mg film-coated tablets, REKAMBYS 900 mg prolonged-release suspension for injection, Viread 245 mg film-coated tablets, Emtriva 200 mg hard capsules, Descovy 200 mg/25 mg film-coated tablets, CELSENTRI 300 mg film-coated tablets, Truvada 200 mg/245 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Odefsey 200 mg/25 mg/25 mg film-coated tablets, STOCRIN 600 mg film-coated tablets, Vocabria 400 mg prolonged-release suspension for injection, INTELENCE 100 mg tablets, Aptivus 250?mg soft capsules, Pifeltro 100 mg film-coated tablets, CELSENTRI 150 mg film-coated tablets, Kivexa 600 mg/300 mg film-coated tablets, ISENTRESS 400 mg film-coated tablets, Fuzeon 90 mg/ml powder and solvent for solution for injection, Vocabria 600 mg prolonged-release suspension for injection, ISENTRESS 600 mg film-coated tablets | Stichting Radboud universitair medisch centrum | HIV-infected | | | | |
2013-002573-22: PROBE TRIAL proof-of-concept study on the use of rilpivirine as substitutive agent for the HAART nucleosidic backbone in virologic suppressed patients STUDIO PROBE rivolto a pazienti con infezione da HIV tratatti con una combinazioen di tre farmaci( due nucleosidici ed un inibitore della proteasi) e che presentano una risposta ottimale con mancata replicazione stabile del virus HIV |
|
|
| Ongoing | 3 | 60 | Europe | Coated tablet, Edurant, Prezista, Norvir | A.O PAPA GIOVANNI XXIII- BERGAMO, janssen | HIV1-infected adults pazienti con infezione HIV, HIV1-infected adults of ≥ 18 years of age on an effective ARV therapy (HIV-RNA < 50 copies/ml) based on the use of two NRTIs and a boosted-PI Adulti con infezione da HIV1 di età ≥ 18 anni con un efficace terapia ARV (HIV-RNA <50 copie / ml), basato sull'utilizzo di due NRTI e un potenziato-PI, Diseases [C] - Immune System Diseases [C20] | | | | |
2014-003419-12: Switch from Efavirenz/Atripla to Rilpivirine Switch da Efavirenz/Atripla a Rilpivirina |
|
|
| Terminated | 3 | 90 | Europe | EVIPLERA, ATRIPLA, Capsule, hard, EVIPLERA, ATRIPLA | AZIENDA OSPEDALIERA SAN GERARDO, MONZA, ITALIA, Gilead Sciences Srl | HIV INFECTION INFEZIONE DA HIV, HIV HIV, Diseases [C] - Immune System Diseases [C20] | | | | |
2016-002413-22: Open label, Randomized clinical trial to evaluate switching from dual regimens to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients Studio in aperto, randomizzato, per valutare il passaggio da una terapia duplice ad una terapia con E/C/F/TAF in pazienti adulti HIV positivi con carica virale negativa. |
|
|
| Terminated | 3 | 100 | Europe | Tivicay (dolutegravir), Emtriva, Lamivudina, Viread, Ziagen, Edurant, Intelence, Sustiva, Viramune, Film-coated tablet, Capsule, hard, Tablet, Prolonged-release tablet, Genvoya¿ 150 mg/150mg/200mg/10mg, TIVICAY - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, EMTRIVA - 30 CAPSULE RIGIDE IN BLISTER DA 200 MG, LAMIVUDINA MYLAN - 300 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/PVDC/AL, VIREAD - 245 MG 30 COMPRESSE RIVESTITE CON FILM IN FLACONE USO ORALE, ZIAGEN - 300 MG COMPRESSE FILMRIVESTITE 6 BLISTER 10 COMPRESSE USO ORALE, EDURANT - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 30 COMPRESSE, INTELENCE - 200 MG - COMPRESSA -USO ORALE - FLACONE (HDPE) 60 COMPRESSE, SUSTIVA - 600 MG COMPRESSE FILM RIVESTITE 1 FLACONE 30 COMPRESSE USO ORALE, VIRAMUNE - 400 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - BLISTER (PVC/AL) 30 COMPRESSE | OSPEDALE SAN RAFFAELE, Gilead Sciences Inc. | HIV infection Infezione da HIV, HIV infected subjects pazienti affetti da virus HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2016-003948-36: A pilot study to evaluate the use of rilpivirine plus darunavir / cobicistat as substitute agents in virologic suppressed patients Studio pilota per valutare l'uso di rilpivirina più darunavir / cobicistat come agenti sostitutivi nei pazienti con carica virologica soppressa |
|
|
| Completed | 3 | 160 | Europe | darunavir+cobicistat, rilpivirina, Film-coated tablet, REZOLSTA - 800 MG/ 150 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE-FLACONE (HDPE)- 30 COMPRESSE, EDURANT - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 30 COMPRESSE | AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII, Janseen- Cilag S.p.A | HIV-1 infection on an effective ARV therapy (HIV-RNA < copies/ml) pazienti con infezione HIV-1 virologicamente soppressi, HIV-1 infection pazienti HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2020-003951-13: Dual therapy in HIV patients in 4 days a week versus 7 days a week Bithérapie chez des patients HIV en 4 jours sur 7 versus 7 jours sur 7 |
|
|
| Completed | 3 | 440 | Europe | Film-coated tablet, TIVICAY, EPIVIR, PREZISTA, EDURANT, NORVIR | INSERM-ANRS, ANRS | HIV infection Infection par le VIH, HIV infection Infection par le VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2022-001437-36: ITACO study and the Analytical Antiretroviral Treatment Interruption study (ITACO-ATI) Studio ITACO e studio sull'interruzione del Trattamento Antiretrovirale (ITACO-ATI) |
|
|
| Not yet recruiting | 3 | 61 | Europe | ODEFSEY, REZOLSTA, BIKTARVY, Triumeq, Edurant, Tivicay, Descovy, Symtuza, Dovato, Epivir, [na], Film-coated tablet, ODEFSEY - 200 MG/25 MG/25 MG- COMPRESSA RIVESTITA- USO ORALE- FLACONE (HDPE) 30 COMPRESSE, REZOLSTA - 800 MG/ 150 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE-FLACONE (HDPE)- 30 COMPRESSE, Biktarvy, TRIUMEQ - 50MG/600MG/300 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE HDPE - 1 FLACONE 30 COMPRESSE, EDURANT - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 30 COMPRESSE, TIVICAY - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, DESCOVY - 200 MG/10 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, Symtuza, DOVATO - 50 MG / 300 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, EPIVIR - 300 MG 1 FLACONE 30 COMPRESSE RIVESTITE CON FILM USO ORALE | IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA, NIH (Johns Hopkins University) | perinatally HIV infection Infezione da HIV perinatale, perinatally HIV infection Infezione da HIV perinatale, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05896761: A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants |
|
|
| Completed | 3 | 118 | Europe, Canada, US, RoW | Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension | ViiV Healthcare, Janssen Research and Development | Human Immunodeficiency Virus Type 1 (HIV-1) | 08/22 | 08/22 | | |
2021-000243-50: Understanding the Impact of HIV-DNA resistance mutations detected by NGS in Simplificationstrategies to 2-Drug Regimens for patients virologically suppressed with previous failures and/orprevious resistance mutations: a prospective multi-centre intervention study (INS-2DR) Impatto delle mutazioni di resistenza rilevate su HIV-DNA con NGS nelle strategie di Semplificazione a regimi a due farmaci in pazienti HIV+ virologicamente soppressi con pregressi fallimenti virologici e/o pregresse mutazioni di resistenza: uno studio prospettico interventistico multi-centrico (INS-2DR) |
|
|
| Terminated | 3 | 210 | Europe | Lamivudina, Pifeltro, Emtriva, Juluca, Janssen-Cilag International NV, Tivicay, Dovato, [-], Tablet, Film-coated tablet, Capsule, hard, Coated tablet, Lamivudina, Pifeltro, Emtriva, Juluca, EDURANT, Tivicay, Dovato | ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI", Ministero della salute | HIV infection Infezione da HIV, HIV infection Infezione da HIV, Diseases [C] - Virus Diseases [C02] | | | | |
LATTE-2, NCT02120352 / 2013-000783-29: A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects |
|
|
| Completed | 2 | 309 | Europe, Canada, US | CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV | ViiV Healthcare, Janssen Pharmaceuticals, GlaxoSmithKline | Infection, Human Immunodeficiency Virus, HIV Infections | 08/15 | 04/23 | | |
NCT04012931 / 2018-004301-32: A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed |
|
|
| Completed | 2 | 26 | Europe, RoW | Rilpivirine, TMC278, ARV Background Regimen | Janssen Research & Development, LLC, Janssen Sciences Ireland Unlimited Company, Janssen Sciences Ireland UC | HIV | 02/23 | 02/23 | | |
2022-000829-24: Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children, 6 to less than 12 years of age, Living with HIV-1 |
|
|
| Not yet recruiting | 2 | 20 | US | JULUCA, J05AR21, Tablet, (GSK3365791 (GSK1349572+GSK1329758); JULUCA (Dolutegravir 50 mg and Rilpivirine 25 mg Fixed Dose Combination Tablet) | ViiV Healthcare UK Limited, ViiV Healthcare, Janssen Research and Development | Virologically Suppressed Children, 6 to less than 12 years of age, Living with HIV-1, HIV-1, Diseases [C] - Virus Diseases [C02] | | | | |
| Withdrawn | 2 | 40 | US | Combined LAI Treatment: Cabenuva and Sublocade, rilpivirine (CAB/RPV) "cabenuva", extended-release buprenorphine (XR-B) "sublocade" | Rhode Island Hospital | Human Immunodeficiency Virus, Opioid Use Disorder | 08/25 | 02/26 | | |
NCT07637877: Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study |
|
|
| Recruiting | 2 | 21 | RoW | cART + Rilpivirine, cART | Beijing 302 Hospital, Shenzhen Third People's Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou Eighth People's Hospital | Immunological Non-Responders in People With HIV | 12/28 | 01/29 | | |
| Active, not recruiting | 2 | 48 | Europe, RoW | Rilpivirine, TMC278, R278474 | Janssen Sciences Ireland UC | HIV-1 Infection | 08/26 | 08/26 | | |
MOCHA, NCT03497676: More Options for Children and Adolescents (): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents |
|
|
| Completed | 1/2 | 168 | US, RoW | Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Edurant, Long-Acting Injectable Cabotegravir (CAB LA), Long-Acting Injectable Rilpivirine (RPV LA), Combination Antiretroviral Therapy (cART) | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 02/23 | 04/25 | | |
| Not yet recruiting | 1/2 | 155 | RoW, US | Cabotegravir LA, Cabotegravir, Rilpivirine, Rilpivirine LA, Suspension for injection, Tablet | National Institute of Allergy and Infectious Diseases, Division of AIDS, ViiV Healthcare UK Limited, Janssen Sciences Ireland UC | HIV-1, HIV-1, Diseases [C] - Virus Diseases [C02] | | | | |
2024-512889-33-00: A roll-over study with rilpivirine for human immunodeficiency virus type 1 (HIV-1) infected subjects who participated in rilpivirine pediatric studies. |
|
|
| Active, not recruiting | 1/2 | 3 | Europe | RILPIVIRINE
, JNJ-16150108 | Janssen Sciences Ireland Unlimited Company | HIV-1 Infection | | | | |
NCT07001488: A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rilpivirine Tablets (RPV) |
|
|
| Completed | 1 | 15 | RoW | Azvudine tablets(FNC) and Rilpivirine Tablets (RPV), Azvudine tablets (FNC) and Rilpivirine Tablets (RPV) | Henan Genuine Biotech Co., Ltd. | Healthy | 05/22 | 01/23 | | |
CTR20213136: Clinical study on the interaction between azvudine tablets (FNC) and rilpivirine tablets (RPV) |
|
|
| Completed | 1 | 15 | China | 1. Chinese Generic Name: Azvudine Tablets; English Generic Name: Azvudine; Brand Name: NA;
2. Chinese Generic Name: Azvudine Tablets; English Generic Name: Azvudine; Brand Name: Shuangxin Aike;
3. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: Enlin | Beijing Union Medical College Pharmaceutical Factory / Henan Zhenshi Biotechnology Co., Ltd. | Indications: For the treatment of patients infected with Human Immunodeficiency Virus (HIV). | | | | |
CTR20200828: Human bioequivalence study of rilpivirine tablets |
|
|
| Not yet recruiting | N/A | 16 | China | 1. Chinese Generic Name: Rilpivirine Tablets; 2. Chinese Generic Name: Rilpivirine Tablets; 1. Chinese Generic Name: Rilpivirine Tablets English Name: Rilpivirine Tablets Brand Name: Edurant | Chengdu Better Pharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients with HIV-1 infection at the onset of infection, whose HIV-1 RNA levels are less than or equal to 100,000 copies/mL. | | | | |
CTR20201589: Human bioequivalence study of rilpivirine tablets |
|
|
| Not yet recruiting | N/A | 80 | China | 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: NA; 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: Edurant | Chengdu Better Pharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients with HIV-1 infection at the onset of infection, whose HIV-1 RNA levels are less than or equal to 100,000 copies/mL. | | | | |
CTR20211288: A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence study evaluating rilpivirine tablets in fasting/postprandial healthy subjects. |
|
|
| Recruiting | N/A | 96 | China | 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: NA; 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: Enlin? | Qilu Pharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients with HIV-1 infection at the onset of infection, whose HIV-1 RNA levels are less than or equal to 100,000 copies/mL. | | | | |
CTR20231478: A randomized, open-label, two-period, two-sequence self-crossover design study evaluating the bioequivalence of a single oral dose of rilpivirine tablets in healthy adults under fasting or postprandial conditions. |
|
|
| Terminated | N/A | 98 | | 1. Chinese Generic Name: Lipiverine Tablets; English Generic Name: Lipiverine Tablets; Brand Name: NA; 1. Chinese Generic Name: Lipiverine Tablets; English Generic Name: Lipiverine Tablets; Brand Name: Edurant? | Shanghai Desano Biopharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients aged 12 years and older with a weight of at least 35 kg who have HIV-1 infection at the start of treatment and whose plasma HIV-1 RNA is less than or equal to 100,000 copies/mL. | | | | |
CTR20261508: Postprandial bioequivalence study of emtricitabine tablets in healthy subjects |
|
|
| Not yet recruiting | N/A | 44 | China | 1. Chinese Generic Name: Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Alafenamide Tablets; English Generic Name: Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Alafenamide Tablets; Brand Name: NA; 1. Chinese Generic Name: Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Alafenamide Tablets; English Generic Name: Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Alafenamide Tablets; Brand Name: ODEFSEY? | Chengdu Better Pharmaceutical Co., Ltd. | Indications: HIV-1 infected patients | | | | |
CTR20210377: Human bioequivalence study of rilpivirine tablets |
|
|
| Completed | N/A | 80 | China | 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: NA; 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: Edurant | Chengdu Better Pharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients with HIV-1 infection at the onset of infection, whose HIV-1 RNA levels are less than or equal to 100,000 copies/mL. | | | | |
NCT06405464: Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures |
|
|
| Recruiting | N/A | 600 | Europe | VOCABRIA 30Mg Tablet, Cabotegravir Tablets, EDURANT 25Mg Tablet, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Vocabria, Rilpivirine Injectable Suspension, Rekambys, Intact proviral DNA assay, Full-length sequencing | University of Zurich, Swiss HIV Cohort Study | HIV Infections | 12/25 | 06/26 | | |
| Completed | N/A | 65 | Europe | Dolutegravir, Raltegravir, Rilpivirine, Nevirapine, Atazanavir, Darunavir, Ritonavir | Assistance Publique - Hôpitaux de Paris, URC-CIC Paris Descartes Necker Cochin | Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed | 06/22 | 06/22 | | |
CTR20220940: Human bioequivalence study of rilpivirine tablets |
|
|
| Completed | N/A | 96 | China | 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: NA; 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: Enlin? | Ruiyang Pharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients aged 12 years and older with a weight of at least 35 kg who have HIV-1 infection at the start of treatment and whose plasma HIV-1 RNA is less than or equal to 100,000 copies/mL. | | | | |
CTR20220535: Human bioequivalence study of emtricitabine, rilpivirine, acetaminophen, and tenofovir tablets |
|
|
| Completed | N/A | 80 | China | 1. Chinese Generic Name: Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Tablets; English Generic Name: Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Tablets; Brand Name: NA; 1. Chinese Generic Name: Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Tablets; English Generic Name: Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Tablets; Brand Name: ODEFSEY? | Qilu Pharmaceutical Co., Ltd. | Indications: For the treatment of adult patients and children weighing ?35 kg with HIV-1 infection. | | | | |
CTR20222217: Human bioequivalence study of rilpivirine tablets (25 mg) |
|
|
| Completed | N/A | 96 | China | 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: NA; 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: Edurant?/??? | Anhui Baker Biopharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients aged 12 years and older with a weight of at least 35 kg who have HIV-1 infection at the start of treatment and whose plasma HIV-1 RNA is less than or equal to 100,000 copies/mL. | | | | |
COMBINE-2, NCT04019873: '': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor |
|
|
| Completed | N/A | 774 | Europe | Dolutegravir (DTG), Lamivudine (3TC), Rilpivirine (RPV) | ViiV Healthcare | HIV Infections | 04/23 | 12/23 | | |
CTR20230945: Human bioequivalence study of dolutegravir/rilpivirine tablets |
|
|
| Completed | N/A | 72 | China | 1. Chinese Generic Name: Dolutegravir Sodium and Rilpivirine Hydrochloride Tablets; English Generic Name: Dolutegravir Sodium and Rilpivirine Hydrochloride Tablets; Brand Name: NA; 1. Chinese Generic Name: Dolutegravir Sodium and Rilpivirine Hydrochloride Tablets; English Generic Name: Dolutegravir Sodium and Rilpivirine Hydrochloride Tablets; Brand Name: JULUCA? | Qilu Pharmaceutical Co., Ltd. | Indications: Treatment of adult human immunodeficiency virus type 1 (HIV-1) infection. | | | | |
| Not yet recruiting | N/A | 280 | NA | Cabotegravir, Rilpivirine Drug Combination | University Paris 7 - Denis Diderot, Hopital Foch | Quality of Life | 04/26 | 10/26 | | |
NCT00537966: Characterization of Acute and Recent HIV-1 Infections in Zurich. |
|
|
| Recruiting | N/A | 800 | Europe | Dolutegravir, Tivicay, Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate, Genvoya, Raltegravir, isentress, Darunavir, Prezista, Ritonavir, Norvir, Rilpivirine, Edurant, Lamivudine, 3TC, tenofovir, Viread, Emtricitabine, Emtriva, Abacavir, Ziagen | University of Zurich | HIV Infections | 12/28 | 12/28 | | |
NCT06704204: Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community |
|
|
| Not yet recruiting | N/A | 20 | NA | The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks | The Miriam Hospital, National Institute on Drug Abuse (NIDA) | HIV | 07/25 | 07/25 | | |
NCT07080138: Research on the Psychological Status of Patients With HIV-1 Infection |
|
|
| Not yet recruiting | N/A | 500 | NA | All kinds of INSTI medications, Bictegravir/Emtricitabine/Tenofovir alafenamide Fumarate, Dolutegravir/Emtricitabine/Tenofovir alafenamide Fumarate, Abacavir/Dolutegravir/Lamivudine, Albuvirtide, Dolutegravir, Dolutegravir/Lamivudine, Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide Fumarate, Emtricitabine/Tenofovir, Emtricitabine/Tenofovir alafenamide Fumarate, Enovirin, Lamivudine/Zidovudine, Raltegravir, Rilpivirine, All kinds of conventional medications, Abacavir, Efavirenz, Emtricitabine, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Tenofovir, Tenofovir alafenamide Fumarate, Zidovudine | Shanxi Bethune Hospital | HIV-1-infection, Anxiety Depression | 07/26 | 12/26 | | |
